The aMAP Score Effectively Stratifies Hepatocellular Carcinoma Risk in the Steatotic Liver Disease Population
Liver International · 2026-11 · 46 (11)
DOI: 10.1111/liv.70936 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, online erschienen am 21.10.2026. Verfasst von Wenxin Xu und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Fatty Liver. Die Arbeit nennt 25 Literaturangaben. Gefördert von: National Science and Technology Major Project.
Abstract (Originalsprache)
Background & Aims Steatotic liver disease (SLD) is an increasingly important cause of hepatocellular carcinoma (HCC), yet validated risk stratification tools remain limited. We aim to evaluate the aMAP score, initially developed for HCC risk prediction mainly in viral hepatitis across international cohorts, in the SLD population.
Methods
156 406 SLD participants were included from the UK Biobank (UKB) and 3166 SLD patients with virally suppressed chronic hepatitis B from a Chinese cohort. The predictive and stratification performance of the aMAP score was assessed and compared with the PAGE‐B, mPAGE‐B, CAMD and MASLD‐HCC scores. A refined stratification of the aMAP‐defined high‐risk population identified a subgroup exceeding the recommended surveillance threshold.
Results
Median follow‐up was 13.64 years in UKB and 9.97 years in the Chinese cohort, with 287 and 58 patients developing HCC, respectively. The aMAP score showed favourable discrimination (C‐indices: 0.80 [95% CI, 0.78–0.83] in UKB; 0.79 [95% CI, 0.73–0.85] in the Chinese cohort). The 15‐year cumulative HCC incidence by aMAP in UKB was 0.06% (95% CI, 0.04%–0.08%), 0.26% (95% CI, 0.21%–0.31%) and 1.43% (95% CI, 1.14%–1.72%) for low‐, intermediate‐ and high‐risk groups (high vs. low risk, sHR: 28.51; 95% CI, 19.58–41.52; Gray's test p < 0.001). Consistent results were found across etiological subgroups and in the other cohort (Gray's test p < 0.001). The refined cutoff (aMAP > 64) identified a very‐high‐risk subgroup in UKB with 15‐year cumulative incidences of 3.08% (training; 95% CI, 1.29%–4.87%) and 5.35% (validation; 95% CI, 3.04%–7.67%).
Conclusions
The aMAP score is an effective tool for HCC risk stratification among SLD patients. The refined aMAP threshold accurately identifies very‐high‐risk patients qualifying for guideline‐recommended surveillance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- Key Laboratory of Infectious Diseases Research in South China, Ministry of Education, Guangzhou, China.
- Guangdong Provincial Key Laboratory for Prevention and Control of Major Liver Diseases, Guangzhou, China.
- Guangdong Provincial Clinical Research Center for Viral Hepatitis, Guangzhou, China.
- Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
- Department of Hepatology, First Hospital, University of Jilin, Changchun, China.
ORCID-Profile: Qing Xie, Huiying Rao, Song Yang, Xiaoguang Dou, Yongfeng Yang, Qiang Li, Hong Tang, Jianqi Lian, Jinlin Hou, Rong Fan
Förderung
- National Science and Technology Major Project
Zitieren
APA
Xu, W., Shi, Y., Liu, Z., Ma, H., Niu, J., Xie, Q., Xie, J., Rao, H., Yang, S., Zhong, C., Dou, X., Xie, D., Yin, J., Sun, A., Yang, Y., Liu, Y., Xu, Y., Li, Q., Jiang, Y., …, & Chronic Hepatitis B Study Consortium (2026). The aMAP Score Effectively Stratifies Hepatocellular Carcinoma Risk in the Steatotic Liver Disease Population. Liver International, 46(11). https://doi.org/10.1111/liv.70936
Vancouver
Xu W, Shi Y, Liu Z, Ma H, Niu J, Xie Q, et al. The aMAP Score Effectively Stratifies Hepatocellular Carcinoma Risk in the Steatotic Liver Disease Population. Liver International. 2026;46(11). doi:10.1111/liv.70936
BibTeX
@article{Xu2026,
author = {Xu, Wenxin and Shi, Yaru and Liu, Zhihong and Ma, Hong and Niu, Junqi and Xie, Qing and Xie, Jianping and Rao, Huiying and Yang, Song and Zhong, Chunxiu and Dou, Xiaoguang and Xie, Dongying and Yin, Junhua and Sun, Aimin and Yang, Yongfeng and Liu, Yali and Xu, Ya and Li, Qiang and Jiang, Yongfang and Li, Wu and Tang, Hong and Lian, Jianqi and Lin, Huapeng and Sun, Jian and Hou, Jinlin and Fan, Rong and Chronic Hepatitis B Study Consortium, Chronic Hepatitis B Study Consortium},
title = {The aMAP Score Effectively Stratifies Hepatocellular Carcinoma Risk in the Steatotic Liver Disease Population},
journal = {Liver International},
year = {2026},
volume = {46},
number = {11},
doi = {10.1111/liv.70936}
}
EUVIMED